Comparing various scoring system for predicting overall survival according to treatment modalities in hepatocellular carcinoma focused on Platelet-albumin-bilirubin

We evaluated the ability of various grading scales including platelet-albumin-bilirubin (PALBI) and albumin-bilirubin (ALBI) grades to predict overall survival (OS) according to treatment modality in patients with hepatocellular carcinoma (HCC). The cohort of 6,669 patients with HCC was selected ran...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2019-05, Vol.14 (5), p.e0216173
Main Authors: Lee, Soon Kyu, Song, Myeong Jun, Kim, Seok Hwan, Park, Misun
Format: Article
Language:English
Subjects:
Ablation (Surgery)
Albumin
Bilirubin
Cancer
Cancer patients
Carcinoma
Health aspects
Hepatitis B
Hepatitis B virus
Hepatocellular carcinoma
Liver
Liver cancer
Liver diseases
Liver transplantation
Medical research
Patient outcomes
Prognosis
Sorafenib
Surgery
Therapeutics
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We evaluated the ability of various grading scales including platelet-albumin-bilirubin (PALBI) and albumin-bilirubin (ALBI) grades to predict overall survival (OS) according to treatment modality in patients with hepatocellular carcinoma (HCC). The cohort of 6,669 patients with HCC was selected randomly from the 2008-2012 national cohort of the Korean Central Cancer Registry. The OS of 6,507 of these patients was evaluated using the Child-Turcotte-Pugh (CTP) class, Model for End-stage Liver Disease (MELD) score, and ALBI and PALBI grades. The patient's mean age was 59.7 years. The most patients were hepatitis B virus (63.4%) and CTP class A (71.8%). The median OS durations of PALBI grade1 (38.4%), grade2 (33.2%), and grade3 (28.4%) patients were 81, 30, and 5 months, respectively (P
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0216173